CLAVENTIN Tablet

- Hypersensitivity to any penicillin.

- Babies born from mother who is hypersensitive to penicillin

- Patients with evidence of cholestatic jaundice (hepatic dysfunction) which connected with penicillin or Co-amoxiclav treatment.

1. Diarrhoea, nausea, vomiting, indigestion, pseudomembranous colitis and candidiasis.

2. A moderate rinse in AST and/or ALT may occur during treatment with semisynthetic penicillins.

3. Hepatitis and cholestatic jaundice may be more severe and continue for several months, especially in adult or elderly patients and slightly more frequently in males. The symptoms may occur during treatment but are more frequently reported after cessation of therapy with a delay of up to 6 weeks. The hepatic events are usually reversible.

4. Urticaria and erythematous rashes.

5. Erythema multiforme, Steven’s-Johnsons syndrome, toxic epidermal necrolysis and exfoliative dermatitis. Treatment should be stopped if these adverse reactions occur.

6. Angioneurotic oedema and anaphylaxis.

7. Interstitial nephritis can occur rarely.

8. Transient leucopenia, thrombocytopenia and anemia hemolytic.

1. Co-amoxiclav may reduce the efficacy of oral contraceptives.

2. Prolongation of bleeding time and prothrombine time in patients receiving anticoagulation therapy.

Administration to pregnancy and lactation women is not recommended, unless considered essential by the physician.

1. Patients with severe hepatic dysfunction.

2. Patients with moderate or severe renal impairment.

3. Administration to pregnancy and lactation women is not recommended, unless considered essential by the physician.

4. 2 tablets CLAVETIN 250mg are not equivalent 1 tablet CLAVENTIN 500mg. Therefore 1 CLAVENTIN 500mg tablet for treatment of more severe infections, should not be substituted with 2 tablets CLAVENTIN 250mg.

5. High dosage and prolonged use may also result super infection) occasionally caused by Enterobacter, Pseudomonas, S.aureus and Candida) in gastrointestinal tract.

Semi synthetic penicillin derivate antibiotic, it is a broad spectrum, effective against gram positive and gram negative.

Amoxicillin acts by inhibit the mycobacterium cell wall synthesis and characterizes bactericidal.

Clavulanic acid will block betalactamase enzyme which is produced by certain bacteria.

The mechanism of action of clavulanic acid occurs in 2 phases:

1. As competitive inhibitor because the chemical structure of clavulanic acid resembles with penicillin, therefore clavulanic acid can replace the active part of enzyme betalactamase structure without any chemical reaction.

2. Carbonyl betalactamase group from clavulanic acid changes penicillinase enzyme become acyl enzyme. The form of acyl enzyme can not destructive the betalactam ring of penicillin.